December #168 : Treatment Twofer - by David Evans

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

The POZ 100

The POZ 100: 1 to 10

The POZ 100: 11 to 20

The POZ 100: 21 to 30

The POZ 100: 31 to 40

The POZ 100: 41 to 50

The POZ 100: 51 to 60

The POZ 100: 61 to 70

The POZ 100: 71 to 80

The POZ 100: 81 to 90

The POZ 100: 91 to 100




Stress Test

Vital Insights From Vienna

Treatment Twofer

HIV Testing Sooner

Worry Wart

Spice It Up




Blood, Sweat and Tears

Positive Rewards

Pop Projects

Party Favors

Men in Love

Hot Dates

Pozarazzi




Editor's Letter

Letters

Healing Touch

GMHC Treatment Issues- December 2010



 
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


Scroll down to comment on this story.


email print

December 2010


Treatment Twofer

by David Evans

ARVs That Fight HIV and Inflammation

A new study suggests that some protease inhibitors (PIs) might be doing double duty—stopping viral reproduction and calming down a hyper-active immune system.

A team led by Luigi Racioppi, PhD, in Italy, looked at the maturation process of a type of immune cell known as dendritic cells (DCs) in the presence of a handful of older PIs. They found that both Norvir (ritonavir) and Invirase (saquinavir) caused newly matured DCs to behave oddly. The cells barely responded to the presence of a bacterium that circulates widely in people with HIV.

In most cases a robust immune response is the goal, but experts now think that chronic inflammation—both against HIV and bacteria that leak out of HIV-damaged cells in the gut—is at the root of a lot of bad stuff, namely cardiovascular disease and certain cancers. In this case, grown-up DCs that don’t overreact to gut bacteria could be just what the doctor ordered.

Racioppi’s team is set to look at newer PIs such as Prezista (darunavir) and Reyataz (atazanavir). Studying the anti-inflammatory properties of these drugs, he says, “would open [new avenues] for designing PIs with more powerful activity on the immune system.”

Search: ARV, inflammation, protease inhibitors, viral reproduction, hyperactive immune system, dendritic cells


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


         

[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    chipper52
    Palm Springs
    California


    july8th69
    brooklyn
    New York


    Heartland4now
    Tacoma
    Washington


    HOTROD2010
    houston
    Texas
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.